Recombinant Bacillus subtilis APT protein, His-tagged
Cat.No. : | APT-1352B |
Product Overview : | Recombinant Bacillus subtilis APT full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | E. coli or Yeast |
Species : | Bacillus subtilis |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | > 80% by SDS-PAGE |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage buffer : | PBS buffer |
Gene Name : | apt adenine phosphoribosyltransferase [ Bacillus subtilis subsp. subtilis str. 168 ] |
Official Symbol : | APT |
Synonyms : | APT; adenine phosphoribosyltransferase |
Gene ID : | 938063 |
UniProt ID : | O34443 |
Products Types
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (24)
Ask a questionCurrently, there is no known cure for APT deficiency. However, management strategies such as dietary modifications and medication can help control symptoms and reduce the risk of complications, particularly kidney stones. Ongoing research may lead to future advancements in treatment options.
Although the primary role of the APT protein is in purine metabolism, there is emerging research suggesting its involvement in other cellular processes. Some studies indicate its potential role in DNA repair mechanisms and cellular response to oxidative stress.
Yes, there are support groups and organizations dedicated to providing information, resources, and support to individuals and families affected by APT deficiency. Examples include the APRT Deficiency Foundation and RareConnect. These organizations offer a platform for connecting with others and sharing experiences.
Understanding the APT protein and its role in purine metabolism is important for developing strategies to treat conditions related to purine nucleotide imbalance. Moreover, targeting the APT protein may have therapeutic applications for diseases like gout, hyperuricemia, or in the development of novel anticancer drugs.
Yes, several compounds have been identified as inhibitors or activators of the APT protein. For instance, some nucleotide analogs can competitively inhibit the enzyme, while certain drugs can enhance its activity to improve purine metabolism.
Yes, there are various known genetic variations and polymorphisms in the APT gene. These variations can impact the activity or expression of the APT protein and contribute to individual differences in purine metabolism and susceptibility to certain diseases.
The APT protein is not specific to humans and is found in various organisms across different species. It is highly conserved throughout evolution, indicating its essential role in purine metabolism.
Yes, APT deficiency is a genetic disorder caused by mutations in the APT gene. It is typically inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the disorder.
In some cases, the APT protein can be used as a diagnostic marker for adenine phosphoribosyltransferase deficiency (APRTD). Measuring the levels of APT enzyme activity or detecting specific mutations in the APT gene can aid in the diagnosis of this disorder.
The expression and activity of APT protein can be regulated by various factors. For example, it can be regulated at the transcriptional level by specific genes, and its activity can be modulated by allosteric regulators or through post-translational modifications.
Yes, ongoing research efforts involve investigating the structure-function relationship of the APT protein, exploring its roles in cellular processes beyond purine metabolism, and developing targeted therapies to modulate APT activity. Additionally, studies are being conducted to identify novel small molecules or compounds that can selectively interact with the APT protein for therapeutic purposes.
Understanding individual variations or mutations in the APT gene can aid in personalized medicine. By identifying specific genetic variations, healthcare providers can tailor treatment strategies based on a patient's unique genetic profile, optimizing the management of conditions related to purine metabolism disorders.
APT deficiency is relatively rare, with an estimated prevalence of approximately 1 in 100,000 individuals worldwide. However, its prevalence may vary among different populations.
The APT protein is predominantly found in the cytoplasm of cells, where it carries out its enzymatic functions.
Yes, there are ongoing research studies and clinical trials investigating various aspects of APT deficiency. These studies aim to better understand the underlying mechanisms of the disorder, improve diagnostic methods, develop new treatments, and enhance patient care. Participation in clinical trials may be an option for individuals with APT deficiency who meet specific criteria and are interested in contributing to scientific advancements in the field.
Yes, the APT protein represents a potential target for therapeutic interventions. Modulating its activity or expression could have therapeutic benefits, such as controlling purine nucleotide levels, treating certain metabolic disorders, or developing new approaches for cancer treatment.
While kidney stones are the most common health problem associated with APT deficiency, there have been reports of other complications such as chronic kidney disease, bladder stones, or chronic urinary tract infections. However, the severity and range of complications can vary among individuals.
Yes, there are treatment options available for APT deficiency. The primary treatment is a low-purine diet, which helps to reduce the production of adenine in the body. Additionally, medications such as allopurinol or febuxostat can be prescribed to inhibit the production of uric acid, which can also help manage the condition.
There have been reports of APT deficiency affecting fertility in some individuals. In males, the presence of kidney stones or obstructed urinary flow due to stone-related complications can lead to infertility. In females, complications related to kidney stones or urinary tract infections may also impact fertility. However, the extent of fertility issues can vary among individuals, and it is recommended to consult with healthcare providers and specialists for personalized guidance.
Yes, prenatal testing can identify APT deficiency if the specific mutation in the APT gene is known. Genetic testing can be performed on fetal cells obtained through procedures like amniocentesis or chorionic villus sampling. However, prenatal diagnosis is not routinely done unless there is a family history of the condition or the parents are known carriers of the gene mutation.
Adenine phosphoribosyltransferase deficiency (APRTD) leads to the accumulation of adenine in the body, which can result in the formation of kidney stones. These kidney stones can cause pain, blood in urine, urinary tract infections, and in severe cases, kidney damage or failure.
Deficiency or mutations in the APT protein can lead to a disorder called adenine phosphoribosyltransferase deficiency (APRTD). This condition can cause the accumulation of toxic levels of adenine, leading to kidney stones and renal failure.
While kidney stones are the primary concern with APT deficiency, long-term complications can arise from recurring kidney stone episodes or complications related to kidney damage. Chronic kidney disease or kidney failure can occur in severe cases. Regular monitoring and appropriate management can help mitigate these risks.
Currently, APT deficiency is not typically included in routine newborn screening programs. However, this may vary depending on the country and its specific screening protocols. In certain cases where there is a family history of APT deficiency or if it is suspected based on symptoms, additional diagnostic testing may be performed after birth.
Customer Reviews (5)
Write a reviewthe manufacturer's commitment to ongoing innovation ensures that I have access to the most advanced and updated versions of the APT protein.
the APT protein offers exceptional quality and purity, which is crucial for ensuring reliable and reproducible experimental outcomes.
the APT protein exhibits remarkable stability, enabling it to maintain its structural integrity and functionality throughout the experimental process.
the manufacturer of the APT protein plays a vital role in supporting my research endeavors.
As a researcher utilizing the APT protein, I am fortunate to benefit from its numerous advantages in trials.
Ask a Question for All APT Products
Required fields are marked with *
My Review for All APT Products
Required fields are marked with *
Inquiry Basket